Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could letting blood pressure drop after heart surgery be safer?

NCT ID NCT06476613

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This pilot study at Massachusetts General Hospital tests whether allowing a slightly lower blood pressure (MAP above 60 mmHg) after heart surgery is safe and reduces the need for blood-pressure-raising drugs. 80 adults having elective heart surgery are randomly assigned to either this 'permissive hypotension' approach or usual care. The goal is to see if this approach is feasible and to gather data for a larger future trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Permissive hypotension (lower blood pressure target of MAP >60 mmHg)
What this could lead to
If successful, this could pave the way for a larger trial that may change how blood pressure is managed after heart surgery, potentially reducing medication use and hospital stays.
What could go wrong
This is a small pilot study (80 people) testing feasibility, not effectiveness. It may not show clear benefits or could reveal risks like organ damage from low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Apr 2024

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Schedules for elective or non-emergent cardiac surgery Exclusion Criteria: * Arrival to the CICU with severe shock determined any of the following: Norepinephrine dose \>20mcg/min, Epinephrine \>3mcg/min, Dobutamine \>2.5mcg/kg/min, Milrinone \>0.2mcg/kg/min * Rapidly increasing pressors within 60 mins of arrival. * Significant prior renal dysfunction (CKD \>4), hemodialysis dependence * Cirrhosis * A neuropathology diagnosis warranting blood pressure goal * Pre-specified MAP goal as determined by clinical team * Carotid stenosis (\> 50%) or prior stroke * Bleeding requiring return to the OR * Need for mechanical circulatory support * Heart and Lung transplantation * Aortic dissection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Surgery

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.